Core Viewpoint - The A-share market has shown a strong performance in 2023, driven by themes such as AI technology, new consumption, and innovative pharmaceuticals, with notable achievements from Changcheng Fund's active equity funds [1] Group 1: Fund Performance - As of July 31, Changcheng Fund has 17 active equity funds ranked in the top 30% of their peers over the past year, showcasing diverse investment directions including innovative pharmaceuticals, new consumption, AI technology, robotics, military electronics, and Hong Kong stocks [1] - In the innovative pharmaceutical sector, funds managed by Tan Xiaobing have excelled, with three funds focusing on the healthcare industry ranking 10/1830, 5/83, and 19/83 in their respective categories over the past year [2] - The Changcheng Innovation-Driven fund, co-managed by Tan Xiaobing and Yang Weiwei, has focused on semiconductors, AI applications, and military sectors, achieving top rankings in their category [3] Group 2: Investment Strategies - Changcheng Fund emphasizes a top-down investment approach, with managers like You Guoliang optimizing their portfolios in AI computing and military sectors, resulting in strong performance rankings [4] - The fund's strategy includes a focus on overseas computing and semiconductor manufacturing, with managers like Shu Wenyu achieving commendable rankings in their respective categories [4] - The fund's diverse investment across various sectors, including military, AI, semiconductors, and new consumption, has led to several funds ranking in the top 30% of their peers [4] Group 3: Future Outlook - Changcheng Fund is committed to fundamental research and the development of a robust investment research system, aiming to enhance active management capabilities and create more value for investors in the future [4]

Group 1 - Central European Fund announced that its two funds, the Central European Science and Technology Innovation Fund and the Central European Medical Innovation Fund, will be subject to subscription limits starting August 11 [1] - The Central European Science and Technology Innovation Fund, managed by Shao Jie, has achieved a return rate of 132.55% since inception, with an annualized return of 14.79% for Class A shares and 39.66% with an annualized return of 13.11% for Class C shares [1] - The Central European Medical Innovation Fund, managed by renowned fund manager Ge Lan, has a return rate of 68.74% for Class A shares and 60.24% for Class C shares since inception, with annualized returns of 8.45% and 7.59% respectively [1] Group 2 - The Central European Science and Technology Innovation Fund focuses on the technology innovation industry, with significant investments in sectors such as smart vehicles, advanced manufacturing processes, self-developed chip IP, and next-generation smart terminals [2] - The top ten holdings of the Central European Science and Technology Innovation Fund include companies like Hengxuan Technology, Lanke Technology, and Ideal Automotive, with the largest holding being Hengxuan Technology valued at approximately 350.59 million yuan [2] - The Central European Medical Innovation Fund primarily invests in stocks related to medical innovation, with a focus on innovative pharmaceuticals and medical devices [2] Group 3 - The top ten holdings of the Central European Medical Innovation Fund include companies such as Sanofi Pharmaceutical, Kelun Pharmaceutical, and WuXi AppTec, with the largest holding being Sanofi Pharmaceutical valued at approximately 729.52 million yuan [4] - Other funds managed by notable managers have also reported strong performance, with year-to-date returns of 84.56% for ICBC Credit Suisse's QDII fund and 82.59% for Great Wall Fund's health-related funds [5][6]

Group 1 - The core point of the news is that China Universal Asset Management has announced a subscription limit for two of its funds, the China Universal Science and Technology Innovation Fund and the China Universal Medical Innovation Fund, starting from August 11, to protect existing investors and maintain stable operations [1] - The China Universal Science and Technology Innovation Fund, managed by Shao Jie, has achieved a return rate of 132.55% since inception, with an annualized return of 14.79% for Class A shares and 39.66% with an annualized return of 13.11% for Class C shares [1] - The China Universal Medical Innovation Fund, managed by renowned fund manager Ge Lan, has a return rate of 68.74% for Class A shares and 60.24% for Class C shares since inception, with annualized returns of 8.45% and 7.59% respectively [1] Group 2 - The China Universal Science and Technology Innovation Fund focuses on the technology innovation industry, with significant investments in sectors such as smart vehicles, advanced manufacturing processes, and self-developed chip IP [2] - The top ten holdings of the China Universal Science and Technology Innovation Fund include companies like Hengxuan Technology, Lanyin Technology, and Tencent Holdings, with total market values ranging from approximately 117 million to 350 million yuan [2] - The China Universal Medical Innovation Fund primarily invests in stocks related to medical innovation, with a focus on innovative pharmaceuticals and medical devices [2][4] Group 3 - The top ten holdings of the China Universal Medical Innovation Fund include companies such as Sanofi Pharmaceutical and WuXi AppTec, with market values ranging from approximately 324 million to 729 million yuan [4] - Other funds managed by different companies, such as ICBC Credit Suisse and Great Wall Fund, have also reported high returns this year, with notable investments in similar sectors [5][6]

Group 1 - The core viewpoint of the article highlights the significant performance of the Chinese innovative pharmaceutical sector, transitioning from storytelling to actual performance realization, leading to substantial gains in both the secondary market and public funds [1][2] - The Wind data indicates that by the end of Q2 2025, the Wande Pharmaceutical Index rose by 26.74%, while the Hang Seng Healthcare Index surged by 47.89% [1] - The Changcheng Pharmaceutical Industry Select Fund, managed by Liang Furui, achieved a remarkable return of 75.18% in the first half of the year, significantly outperforming its benchmark of 6.08% and the average performance of similar mixed funds at 7.79% [1] Group 2 - Changcheng Fund's pharmaceutical research team, led by veteran Tan Xiaobing, emphasizes a "learning from the old" approach, building a team with strong pharmaceutical backgrounds and extensive investment research experience [2][3] - Tan Xiaobing's management of funds such as Changcheng Health A and Changcheng Pharmaceutical Technology Six-Month Holding A yielded returns of 42.94%, 41.40%, and 32.19% respectively, validating the effectiveness of their investment logic [2] Group 3 - The investment strategy of Tan Xiaobing focuses on a multi-faceted approach covering "policy + technology + industry chain," targeting innovative drugs that benefit from policy support and have clinical value [3] - The Changcheng Medical Care A fund adopts a comprehensive industry chain perspective, covering medical devices and biological products, thus capturing opportunities throughout the entire development cycle [3] Group 4 - Long Yu Fei, another key member of the Changcheng Fund's pharmaceutical research team, focuses on the "AI + healthcare" sector, exploring innovative applications of AI in diagnostics and drug development [4] - The collaborative culture within the Changcheng Fund promotes knowledge sharing and cross-disciplinary cooperation, enhancing decision-making efficiency and reducing risks associated with single-sector investments [4]